A Study for PRO of CML in Real Word

• Conditions: CML (Chronic Myelogenous Leukemia)

• Registration Number: NCT05092048
• Lead Sponsor: xuna

Brief Summary

Successful outcomes in CML require both prolonged adherence to oral TKI therapy by patients and careful monitoring of treatment responses by their physicians. Patient Reported Outcomes(PRO) assessment is important to facilitate decisions in the current treatment landscape of CML.

Detailed Description

1. Above 18 years of age.

2. Patient with confirmed diagnosis of Philadelphia chromosome positive and/or BCR-ABL positive chronic myeloid leukemia (CML).

3. Written informed consent.

4. Patients enrolled in investigational drug-trials or other type of clinical trials are also eligible.

Study Timeline

• Status Verified: 2021-09
• Study Start: 2021-09-22
• Study First Submitted: 2021-09-22
• Study First Submitted QC: 2021-10-11
• Last Update Submitted: 2021-10-11
• Study First Posted: 2021-10-25
• Last Update Posted: 2021-10-25
• Primary Completion: 2022-09-30
• Study Completion: 2022-10-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Not specified
• Target Recruitment: 10000

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Assess health-related Quality of Life and Symptom Burden in patients with chronic myeloid leukemia	1 year	Health-related quality of life (HRQOL) assessment in the current treatment landscape of chronic myeloid leukemia

Trial Locations

Locations (1)

Department of Hematology, Nanfang Hospital, Southern Medical University,; 🇨🇳 Guanzhou, China

Department of Hematology, Nanfang Hospital, Southern Medical University,

🇨🇳Guanzhou, China

Department of Hematology Nanfang Hospital Southern M University

Contact

02062787883

292347668@qq.com